New Cancer Drug Approvals Linked to Drop in Mortality
New cancer drugs approved between 2000 and 2016 associated with 1,291,769 fewer related deaths in the U.S.
Medicare Outpatient Premium to Rise
Monthly premium for outpatient care will rise by $3.90 next year
Panel Recommends Against Approval of Experimental Drug for Alzheimer Disease
FDA panel concluded there is not enough evidence to support the clinical effectiveness of aducanumab
COVID-19-Linked Ischemic Strokes More Severe
More severe disability on discharge and more inpatient death reported for ischemic stroke in COVID-19 patients versus controls
Multinutrient Intervention Slows Cognitive Decline in Alzheimer Disease
Cognitive decline significantly reduced for Neuropsychological Test Battery five-item composite, memory, brain atrophy measures
Considerable Decreases Seen in Health Care Use During COVID-19
Reductions reported in colonoscopies, mammograms, child vaccines, in-person office visits; telemedicine service use up in March, April 2020
Global Burden High for Musculoskeletal Disorders
From 1990, slight decrease seen in age-standardized prevalence, disability-adjusted life year rates
Regulators Discuss Approval of New Alzheimer Disease Drug
Aducanumab does not cure or reverse Alzheimer disease; high dose may slow mental decline
Restricting Symptoms at the End of Life Decreasing
Decreases seen for difficulty sleeping; chest pain or tightness; shortness of breath; cold or flu symptoms; and nausea, vomiting, or diarrhea
Rate of Memory Decline Greater for Mothers Who Do Not Work for Pay
Average rate of memory decline after age 60 greater for women who did not work for pay after childbearing
